DexCom, Inc. (DXCM) on Decifer

Decifer ranks DXCM number 223 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 17% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 16% a year, profits grew 47% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• It trades about 67% above similar companies, and its growth does not yet back up that price.
• A valuation about 67% above peers blocks the path for 17% returns and 47% profit growth with no worldview role.

The current read

The evidence on DXCM lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full DXCM research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.